Cargando…
Impact of FDA Updates on Public Interest in Breast Implant-associated Anaplastic Large Cell Lymphoma
In the United States, the Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety, efficacy, and security of drugs, biological products, and medical devices. In that role, FDA releases timely updates with regard to medical devices and their possible...
Autores principales: | Singh, Mansher, Singh, Gayatri, Singh Chauhan, Anupam, Lee, Harrison H., Sacks, Justin M., Hultman, Charles S., Albert, Mark G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722577/ https://www.ncbi.nlm.nih.gov/pubmed/33299706 http://dx.doi.org/10.1097/GOX.0000000000003240 |
Ejemplares similares
-
Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants
por: Hyland, Colby J., et al.
Publicado: (2022) -
Public Awareness of Breast Implant-associated Anaplastic Large Cell Lymphoma in Saudi Arabia
por: Mrad, Mohamed Amir, et al.
Publicado: (2021) -
Breast Implant-associated Anaplastic Large Cell Lymphoma: A Canadian Surgical Oncology Survey
por: Azzi, Alain J., et al.
Publicado: (2020) -
Analysis of Popular Social Media Addressing Breast Augmentation, Implants, and Anaplastic Large Cell Lymphoma
por: Ben-Naftali, Yeela, et al.
Publicado: (2021) -
Breast Implant-associated Anaplastic Large Cell Lymphoma after Breast Reconstruction for Breast Cancer
por: Mesa, Felipe, et al.
Publicado: (2023)